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Abstract: 
Background: The prognostic value of the systemic inflammatory response in cancer has 
been well established in observational studies. This review aims to examine and rationalise 
the evidence for the role of systemic inflammation based prognostic scores in randomised 
clinical trials. 
Method: An extensive literature review using targeted medical subject headings was carried 
out in the MEDLINE, EMBASE, and CDSR databases until January 2018.  Titles were 
examined for relevance and after exclusions bibliographies were hand searched to identify 
additional trials.  
Results: There were 29 trials containing data on 37,020 patients presented in full paper form 
and 8 trials containing data on 3,805 patients presented in abstract form.  Most trials were 
published within the last three years. Seven trials containing data on 6,044 patients were 
published in 2015. Eight trials containing data on 4,384 patients were published in 2016. 
Twelve trials containing data on 27,228 patients were published in 2017. The majority of 
trials were in advanced inoperable cancer and colorectal cancer was the most common cancer 
type with 11 articles containing data on 27,909 patients.  The GPS/mGPS was shown to have 
prognostic value in randomised clinical trials in NSCLC, oesophageal cancer, pancreatic 
cancer, prostate cancer and breast cancer. The NLR/dNLR was shown to have prognostic 
value in randomised clinical trials in nasopharyngeal cancer, oesophageal cancer, pancreatic 
cancer, biliary cancer, prostate cancer and multiple cancer types. 
Conclusion: The prognostic value of systemic inflammation based prognostic scores has 
been confirmed in multiple trials and should be incorporated into future prospective 
randomised clinical trials. 
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Introduction:  
Cancer remains one of the leading causes of mortality worldwide and is responsible for 
8.8 million deaths each year. In the westernised countries, it has been estimated that one in 
three people will develop cancer in their lifetime, and one in four will die from it. Such a 
large burden of disease accounts for a significant proportion of the healthcare budgets in the 
UK, US and worldwide (Bosanquet and Sikora, 2004; Organization, 2017).  
The prognostic value of the systemic inflammatory response in cancer has been well 
established in observational studies.  Over the course of the last 30 years multiple markers of 
the systemic inflammatory response such as C-reactive protein, albumin, neutrophil count, 
lymphocyte count and that of other white cells have been reported to have prognostic value in 
patients with cancer, at all stages of disease (Guthrie et al., 2013; McMillan, 2013).  In the 
last 15 years there has been a movement towards the use of combined prognostic scores such 
as the GPS/mGPS (C-reactive protein and albumin) and ratios such as the NLR (neutrophils 
and lymphocytes) to standardise and maximise prognostic value (Dolan et al., 2017a; Dolan 
et al., 2017b).  
Despite the proven utility of these prognostic tools there has been an ongoing reluctance 
by the oncology community to incorporate these into routine clinical trial design.  In 2012, 
MacDonald commented “The seminal observation by McMillan and colleagues that the 
presence of a dysregulated state as evidenced by a high CRP connotes a dire prognosis has 
been generally ignored to date and not used to stratify patients in oncology clinical trials. 
Particularly in the more aggressive tumour types (e.g. pancreas and lung), the future of 
patients with elevated mGPS scores is so grim that they should be given precachexia status 
and offered multimodal therapy which may delay the onset of cachexia and/or death 
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(MacDonald, 2012).”   More recently, Laird and co-workers in large prospective cohorts of 
patients with advanced cancer have added weight to this assertion (Laird et al., 2016; Laird et 
al., 2013).  
Based on work to date and the sound rationale for the use of prognostic tools in oncology 
trials, the aim of this systematic review was to examine and rationalise the evidence for the 
role of systemic inflammation based prognostic scores in the setting of randomised control 
trials.  
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Methods: 
This systematic review of published literature was undertaken according to a pre-defined 
protocol described in the PRISMA-P statement and in a similar fashion to that recently 
reported with both  advanced inoperable and operable cancer (Dolan et al., 2017a; Dolan et 
al., 2017b). Inclusion criteria consisted of randomised controlled clinical trials carried out in 
adult patients (aged 18-99) with curable and incurable cancer treated with any systemic anti-
cancer therapy using validated combined scores of the systemic inflammatory response in 
both prospective and retrospective analysis with a primary outcome measure of survival. The 
primary aim was to assess the prognostic value of the validated combined scores of the 
systemic inflammatory response (NLR, PLR, LMR, GPS and mGPS) in the setting of 
randomised controlled clinical trials.  
This was carried out by a wide-ranging literature search to identify trials carried out from 
January 1947 to 31st January 2018. Medical subject heading (MeSH) terms (Cancer, 
Randomised Control Trial, GPS, Glasgow Prognostic Score, mGPS, modified Glasgow 
Prognostic Score, NLR, Neutrophil Lymphocyte Ratio, LMR, Leucocyte Monocyte Ratio, 
PLR, Platelet Lymphocyte Ratio), were used in the US National Library of Medicine 
(MEDLINE), the Excerpta Medica database (EMBASE) and the Cochrane Database of 
Systematic Reviews (CDSR) to identify published papers and abstracts.  
On completion of the online search, the title and abstract of each identified study was 
examined for relevance. Animal studies, those not in cancer patients, and trials not available 
in English were excluded. Where there were multiple publications from the same cohort the 
most recent paper was included. Once further exclusions outlined below were carried out, the 
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bibliographies of all included articles were subsequently hand searched to identify any 
additional trials. All potentially eligible papers were reviewed in full by two authors 
independently and graded according to GRADE recommendations. 
Only articles that reported survival were included. Results were reported in terms of (1) 
cancer type and (2) combined markers of the systemic inflammatory response used.   
Figure 1: PRISMA flowchart demonstrating study selection 
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Results:  
The study selection process is summarised in Figure 1. Initial search strategy identified 
382 papers and abstracts whose titles and abstracts were reviewed. Trials were excluded as 
they were not clinical trials (n=173) and as survival was not their primary measure (n=72).  
This led to a review of the full text of 137 articles. A further 106 articles were excluded as 
they were not in English (n=51), were animal studies (n=32), were not carried out in patients 
with cancer (n=20) and were carried out in duplicate datasets (n=3).  The remaining 31 
articles, had their bibliographies reviewed in a systematic manner and this identified a further 
5 articles to be included in the final analysis leading to final figure of 36 reports containing 
data on 40,354 patients considered in the present systematic review (Tables 1 and 2).  
There were 28 trials containing data on 36,549 patients presented in full paper form and 8 
trials containing data on 3,805 patients presented in abstract form.  Most trials were published 
within the last three years. Seven trials containing data on 6,044 patients were published in 
2015. Seven trials containing data on 3,913 patients were published in 2016. Twelve trials 
containing data on 27,228 patients were published in 2017. In all 36 trials the predominant 
treatments being investigated was chemotherapy and radiotherapy. The majority of trials 
were in advanced inoperable cancer and colorectal cancer was most common cancer type 
with 10 articles containing data on 27,438 patients.   
The prognostic utility of the GPS/mGPS was assessed in 7 trials with data on 1,284 
patients and NLR/dNLR was assessed in 33 trials with data on 39,313 patients. All 36 trials 
were analysed in a post hoc manner. The thresholds used for GPS/mGPS were the same in all 
trials. The GPS/mGPS was shown to have prognostic value in randomised clinical trials in 
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NSCLC (Rinehart et al., 2013), oesophageal cancer (Okuno et al., 2017), pancreatic cancer 
(Hurwitz et al., 2015), prostate cancer (Linton et al., 2013) and breast cancer (Honecker et al., 
2017). The thresholds for NLR varied between 3 to 6 and for dNLR between 2 to 5. The most 
common threshold for NLR was ≥3 and was used in 9 trials containing data on 4,042 patients. 
The most common threshold for dNLR was 2 and was used in 3 trials containing data on 
3,810 patients. The NLR/dNLR was shown to have prognostic value in randomised clinical 
trials in nasopharyngeal cancer (Chua et al., 2016), oesophageal cancer (Cox et al., 2017), 
pancreatic cancer (Vivaldi et al., 2016), biliary cancer (Grenader et al., 2015), prostate cancer 
(van Soest et al., 2015) and multiple cancer types (Kumar et al., 2015). A combination of 
both GPS/mGPS and NLR/dNLR were measured in 2 trials containing data on 461 patients 
(Chua et al., 2012; Thomsen et al., 2016). Thomsen and colleagues showed that both mGPS 
(HR: 2.16, 95%CI 1.52-3.06, p<0.001) and dNLR (HR: 1.68, 95%CI 1.35-2.08, p<0.001) 
were prognostic in 68 patients with multiple cancer types (Thomsen et al., 2016). Chua and 
colleagues showed that both GPS (HR: 4.1, 95%CI 2.2-7.7, p<0.0001) and NLR (HR: 2.0, 
95%CI 1.2-3.3, p=0.010) were prognostic in 393 patients with colorectal cancer (Chua et al., 
2012). 
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Discussion:  
The results of the present systematic review are consistent with previous observational 
studies and confirm the clinical utility and prognostic value of systemic inflammation based 
prognostic tools in the randomised control trial setting. Therefore, we propose that the time 
has now come for the universal incorporation of measures of the systemic inflammatory 
response into the design of randomised clinical trials in patients with cancer. Monitoring of 
both tumour and host responses will enable a more reliable estimate of benefit from 
oncological treatment. This will in turn highlight opportunities not only to target the tumour 
but also host systemic inflammatory responses. 
Despite supportive meta-analysis of hundreds of reports of the prognostic value of 
markers of the SIR(Dolan et al., 2017a; Dolan et al., 2017b) , one of the main reasons for the 
lack of incorporation on monitoring of the systemic inflammatory response into standard 
randomised control trial protocols has been the apparent lack of prospective data and also the 
lack of a clear biological rationale behind their clinical utility. Therefore, the present review 
has only included prospective randomised trials and these confirm the prognostic value of the 
SIR. Moreover, with the explosion of interest in immunological treatments in patients with 
cancer, including several dedicated journals, the biological rationale for such systemic 
inflammation based prognostic scores has now become clear(Rosales, 2018; Roxburgh and 
McMillan, 2015). It remains to be established which of the markers of the SIR will be used in 
the RCT setting. However, compared with a ratio such as the NLR with its variable and 
poorly defined cut-off, a score such as the GPS with its well defined cut-off has a clear 
advantage(Dolan et al., 2018). 
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In the present systematic review only two small RCTs reported two measures of the Systemic 
Inflammatory Response (SIR) and in both trials the GPS/mGPS and the NLR/dNLR were 
shown to have independent prognostic value (Chua et al., 2012; Thomsen et al., 2016). 
Therefore, in the context of the large preponderance of RCTs using NLR/dNLR it would 
suggest that NLR/dNLR should become the tool of choice for the measurement of the SIR in 
randomised trials. However, recently the NLR/ dNLR ratio approach to combining markers 
of the SIR as a prognostic tool has been questioned (Dolan et al., 2018; Dupre and Malik, 
2018).   
In particular it is not clear from a ratio what component is abnormal, what component is 
the prognostic value derived from and therefore the optimal threshold for prognostic value. 
This is confirmed in the variety of thresholds that have been reported for NLR/dNLR both in 
observational studies and the RCT setting. In contrast, the cumulative score approach such as 
the GPS/mGPS uses consistent thresholds and have been successfully applied to the RCT 
setting.  Although, in many centres in the USA CRP has not been routinely measured either 
in clinical oncology practice or in the randomised control trial setting, recently CRP, albumin, 
and NLR have been listed as mandatory measurements in the first international consensus on 
mandatory baseline and prognostic characteristics in future trials for the treatment of 
unresectable pancreatic cancer (Ter Veer et al., 2018).  
The advantage of a differential white cell count on which to base a prognostic score is 
that currently it is universally examined in clinical practice in patients with cancer.  We have 
recently proposed that a number of scores based on the differential white cell count could be 
used to replace the ratios currently used (Dolan et al., 2018). For example, the neutrophil 
lymphocyte score (NLS) could replace the NLR, the platelet lymphocyte score (PLS) could 
replace the PLR and the lymphocyte monocyte score (LMS) could replace the LMR (Dolan et 
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al., 2018).  Indeed, recent analysis of the ARCAD database of >22,000 patients with 
advanced colorectal cancer confirms the value of the cumulative score approach compared 
with the ratio approach (Sjoquist et al., 2017). 
In summary, the prognostic value of systemic inflammation-based prognostic scores 
established extensively in observational studies over the past two decades has now been 
confirmed in the randomised controlled setting.  The time has now come for prospective 
incorporation of such scores into randomised controlled trials in patients with cancer.
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Authors Randomised 
Clinical 
Trial  
Tumour Type Country  Patients 
(n) 
Randomised Clinical Trial Systemic 
Inflammation 
Outcome Comment 
Rinehart et al. 
(2013)  
DEX NSCLC United States 124 Standard chemotherapy vs. Standard 
chemotherapy and Dexamethasone  
GPS OS Univariate analysis: 
GPS: p< 0.05  
Lee et al. 
(2012)  
First-SIGNAL 
NCT00455936 
Lung Korea 199 Gefitinib plus gemcitabine plus cisplatin vs 
gefitinib monotherapy  
NLR OS Multivariate 
Post treatment NLR>2.52 
HR 1.13, 95%CI 1.06-1.21, p<0.001 
Chua et al. 
(2016)  
SQNP01 
 
 
 
NCC0901 
Naso-
pharyngeal 
Singapore 221 
 
 
 
172 
Two-dimensional radiotherapy vs.  Two-
dimensional radiotherapy and 
chemotherapy 
 
Intensity modulated radiotherapy or 
concurrent chemotherapy vs. Intensity 
modulated radiotherapy and chemotherapy  
NLR OS Multivariate: 
NLR≥3: 
HR 1.06, 95%CI 0.76-1.49, p>0.05 
 
Cox et al. 
(2017)  
SCOPE1: 
NCT00509561 
Oesophageal United 
Kingdom 
258 Chemoradiotherapy vs Chemoradiotherapy 
and cetuximab 
dNLR OS Multivariate 
dNLR≥2  
HR 1.64 95%CI 1.17-2.29, p<0.01 
Okuno et al. 
(2017)  
JCOG0303: 
UMIN00000086
1 
Oesophageal Japan 142 Radiotherapy and standard cisplatin vs. 
Radiotherapy and low dose cisplatin  
GPS OS Univariate 
GPS 2 vs GPS 0 
HR 1.95 95%CI 1.19-3.18, p<0.01 
Grenader et 
al. (2016)  
REAL-2 
ISRCTN516788
83  
Oesophago-
gastric 
United 
Kingdom  
908 Epirubicin and cisplatin and either 
fluorouracil (ECF) or capecitabine (ECX) 
vs Epirubicin and oxaliplatin and  either 
fluorouracil (EOF) or capecitabine (EOX) 
NLR OS Multivariate 
NLR>3 
HR 1.67 95% CI 1.45–1.93 p<0.001 
 
Bruix et al. 
(2017)  
Sharp 
NCT00105443 
AP: 
NCT00492752 
Hepatocellular Multinational 827 Sorafenib vs. Placebo NLR OS Multivariate  
NLR>3 (Sorafenib group) 
HR 2.356, p<0.0001 
 
NLR>3.86 (Placebo group) 
HR 1.779, p<0.0001  
Grenader et 
al. (2015)  
ABC-02: 
NCT00262769 
 
BT-22: 
UMIN 
000001685 
 
Biliary United 
Kingdom  
 
Japan  
462 Gemcitabine vs. Gemcitabine and cisplatin 
Gemcitabine vs. Gemcitabine and cisplatin  
dNLR OS Multivariate 
dNLR≥3 
HR 1.62, 95% CI 1.32–2.01, p<0.001 
Vivaldi et al. 
(2016)  
FLAP: 
NCT02351219 
Pancreatic  Italy  137 Neoadjuvant FOLFOXIRI and Surgery vs 
Neoadjuvant FOLFOXIRI and radiotherapy  
NLR  OS Multivariate 
NLR ≥4 
HR 2.42, 95%CI: 1.38-4.25, p<0.01 
Hurwitz et al. 
(2015)  
RECAP: 
NCT01423604 
Pancreatic United States 127 Capecitabine vs Capecitabine and 
ruxolitinib 
mGPS OS Univariate 
mGPS 1/2 vs mGPS 0 
HR 0.60, 95%CI 0.35-1.03, p<0.10 
Goldstein et 
al. (2015)  
MPACT: 
NCT00844649 
Pancreatic Multinational  861 Gemcitabine vs Gemcitabine and nab-
paclitaxel 
NLR OS Multivariate 
NLR≤5 
HR 0.57, 95%CI 0.48-0.68, p<0.001 
Renfro et al. 
(2017)  
Multiple in 
ARCAD 
database  
Colorectal  Multinational  22,654 Multiple chemotherapy trials  dNLR 30 day OS Multivariate 
dNLR≥5 
HR 1.74, 95%CI 1.25-2.41, p<0.01 
Wood et al. 
(2017)  
COIN: 
NCT00182715 
Colorectal United 
Kingdom and 
Ireland 
1630 Oxaliplatin/fluoropyrimidine combination 
chemotherapy vs  
oxaliplatin/fluoropyrimidine combination 
chemotherapy and Cetuximab 
dNLR OS Univariate 
dNLR≥2.2 
HR 1.35, 95%CI 1.20-1.52, p<0.001  
 
Thomsen et 
al. (2016)  
NORDIC-VII: 
NCT00660582 
Colorectal Norway and 
Denmark  
393 Cetuximab and FLOX vs. Cetuximab and 
intermittent FLOX 
mGPS, dNLR OS Univariate 
mGPS1 vs 0 
HR 1.60, 95%CI 1.27-2.01, p<0.001 
 
mGPS 0 vs 2 
HR : 2.16, 95%CI 1.52-3.06, p<0.001 
 
dNLR>2.1 
HR : 1.68, 95%CI 1.35-2.08, p<0.001  
Passardi et al. 
(2016)  
ITACa: 
NCT01878422 
Colorectal Italy 289 Standard chemotherapy vs. either FOLFIRI 
or FOLFOX4 and bevacizumab. 
NLR OS Multivariate 
NLR ≥3 
HR:1.78, 95%CI: 1.17-2.70, p<0.01 
Correale et al. 
(2014)  
GOLFIG-2 
EUDRACT: 
2005-003458-81 
Colorectal Italy 124 Gemcitabine, Oxaliplatin, Levofolinate, 5-
Fluorouracil, Granulocyte-Macrophage 
Colony-Stimulating Factor, and Interleukin-
2 (GOLFIG) Vs. FOLFOX Chemotherapy 
NLR OS Univariate 
NLR< 3 
HR 0.44, P< 0.001 
Hazama et al. 
(2014)  
Phase 1 
HLA2402 
matched  
Colorectal  Japan 96 Comparison of five HLA-A*2402-restricted 
peptides, three derived from oncoantigens 
and two from vascular endothelial growth 
factor (VEGF)  
NLR OS Univariate analysis: 
NLR≥3: p<0.05 
Lorente et al. 
(2015)  
Phase III 
TROPC trial  
Prostate United 
Kingdom 
755 Cabazitaxel vs. mitoxantrone NLR OS Multivariate 
NLR≥3 
HR 1.55, 95% CI 1.3– 1.84, p<0.001 
Van Soest et 
al. (2015)  
VENICE: 
NCT00519285 
 
 
Prostate Multinational  1224 
  
 
 
1006 
Docetaxel/ prednisone and placebo vs 
Docetaxel/ prednisone and aflibercept 
 
 
dNLR OS Multivariate 
dNLR ≥2.0 
HR 1.29, 95% CI 1.11–1.50, p<0.001 
 
dNLR ≥2.0 
TAX327:  
NCT01487902 
 Docetaxel/ prednisone and placebo vs 
Docetaxel/ prednisone and mitoxantrone 
HR 1.43, 95% CI 1.20–1.70, p<0.001 
Sonpavde et 
al. (2014)  
SUN-1120:  
NCT00676650 
Prostate Multinational  848 Prednisone and sunitinib or placebo 
following docetaxel monotherpy  
NLR OS Multivariate  
NLR Log-transformed 
HR 1.55, 95%CI 1.32-1.83, p<0.001  
Linton et al. 
(2013)  
AT-101-CS-
205:  
NCT00571675 
Prostate United States 
and Russia 
220 Docetaxel/prednisone vs Docetaxel/ 
pednisone and AT101 
mGPS 
 
OS Multivariate 
mGPS  
HR 1.87, 95% CI 1.35-2.59, p<0.001 
 
mGPS 2 vs 0 
HR 3.44, 95%CI 1.75-6.76, p<0.001 
Fox et al. 
(2013)  
EGF20001 Renal Multinational  362 Lapatinib versus hormone therapy 
 
NLR 
 
 
 
PLR 
OS Multivariate: 
NLR>3 
HR 1.42, 95%CI 1.10-1.84, p=0.008 
 
Univariate: 
PLR>195 
HR 1.88, 95%CI 1.48-2.37, p<0.0001 
Ojerholm et 
al. (2017)  
SWOG8710: 
NCT02756637 
Bladder United States 230 Cystectomy plus neoadjuvant 
chemotherapy vs. cystectomy alone 
NLR OS  Multivariate 
NLR (continuous) 
HR 1.04, 95%CI 0.98-1.11, p=0.24 
Honecker et 
al. (2017)  
PELICAN:  
NCT00266799 
Breast Germany 210 First-line pegylated liposomal doxorubicin 
(PLD) vs. capecitabine. 
GPS OS Multivariate 
GPS: p<0.10 
Romano et al. 
(2015)  
Multiple:  
GIMEMA 
MMY-3006, 
GIMEMA 
MM03-05, RV-
MM-PI209, 
J0231 
Multiple 
Myleoma  
Italy  309 Multiple trials on newly diagnosed multiple 
myeloma treated with novel therapies  
NLR OS Univariate analysis: 
NLR≥2: p=0.0002 
Bigot et al. 
(2017)  
ICT –Phase 1 
trial  
Multiple France  155 Standard treatment vs. Immune checkpoint 
treatment 
NLR OS Multivariate 
NLR≥6  
HR 1.75, 95%CI 1.04-2.94, p<0.05  
Kumar et al. 
(2015)  
Multiple 
Phase 1 (RMH) 
Multiple United 
Kingdom 
1300 Dose and toxicity finding study for 
chemotherapy in multiple phase 1 
chemotherapy trials  
NLR OS Univariate 
Test Cohort, NLR>4.45  
HR 1.78, 95%CI 1.41-2.87, p<.0001 
 
Validation Cohort, NLR>4.45 
HR 1.57, 95%CI 1.42-1.97, p<0.001 
Chua et al. 
(2012)  
Single Agent 
Phase 1   
Multiple Australia  68 Docetaxel monotherapy vs. standard 
treatment  
GPS 
NLR 
OS Multivariate 
GPS 
HR 4.1, 95%CI 2.2-7.7, p<0.0001 
 
NLR>5 
HR 2.0, 95%CI 1.2-3.3, p=0.010 
 
 
 
 
Table 2: The relationship between the systemic inflammatory response and survival in randomised clinical trials in patients with cancer (published abstracts) 
Authors Randomised 
Clinical 
Trial  
Tumour Type Country  Patients 
(n) 
Randomised Clinical Trial Systemic 
Inflammation 
Outcome Comment 
Diakos et al. 
(2016a)  
CO.17 
NCT00640471  
 
CO.20 
NCT00079066 
Colorectal Australia and 
Canada 
572 
 
 
  
750 
CO.17: Cetuximab vs. best 
supportive care, 
 
 
CO.20:  Brivanib (B) vs. placebo 
dNLR  OS Multivariate 
dNLR≥2 
CO.17  HR 1.4, 95% CI 1.1-1.8, p <0.01 
 
CO.20 HR 1.4, 95% CI 1.2-1.6, p<0.0001  
Diakos et al. 
(2016b)  
AGITG MAX Colorectal Australia 471 Capecitabine and bevacizumab vs. 
Capecitabine and bevacizumab and 
mitomycin C 
NLR OS Multivariate 
NLR≥5 
HR 1.8, 95%CI 1.3-2.3, p<.0001  
De Maio et al. 
(2017)  
ECRTC 
62043/62072 
Sarcoma Belgium  333 Pazopanib vs placebo NLR OS Univariate 
NLR>3 
HR 1.86, 95%CI 1.43-2.41, p<0.001 
Coleman et al. 
(2017)  
Phase 1 Trial Recurrent 
Primary 
Malignant Brain 
Tumour 
United 
Kingdom 
100 Primary corticosteroid vs. best supportive 
care 
NLR OS Multivariate 
NLR≥4 
HR 1.73, 95%CI 1.02-2.94, p=0.043 
Wang-Gillam 
et al. (2017)  
NAPOLI-1: 
NCT01494506 
Pancreatic Multinational  116 Iposomal irinotecan + 5-fluorouracil and 
leucovorin vs 5-fluorouracil and leucovorin 
alone 
NLR 
 
 
 
PLR 
OS Univariate 
NLR≤5 
HR 0.62, 95%CI 0.44-0.86, p=0.005 
 
PLR≤150 
HR 0.52, 95%CI 0.32-0.84, p=0.008 
Smyth et al. 
(2017)  
REAL 3: 
NCT00824785 
Oesophagogastric  United 
Kingdom  
553 Epirubicin, Oxaliplatin, Capecitabine 
(EOC) vs  EOC plus panitumumab (EOC-
P) 
NLR OS Univariate 
NLR: Upper Tertile 
EOC cohort 
HR: 9.97, 95%CI 7.43-15.43, p<0.001 
 
ECP-P cohort 
HR: 5.26, 95%CI 4.28-7.17, p<0.001 
 
Clarke et al. 
(2018)  
ASCENT: 
NCT01588990 
Colorectal  Australia 128 First line BEV+XELOX or mFOLFOX6 in 
phase A (PhA) with planned continuation 
of BEV+FOLFIRI beyond 1st progression 
in phase B (PhB). 
NLR OS Univariate: 
NLR>5 
HR: 1.6, 95% CI 1.0-2.7, p = 0.052 
Argiles et al. 
(2018)  
RECOURSE: 
NCT01607957 
Colorectal  Multinational  782 Trifluridine/tipiracil (TAS-102) vs placebo NLR OS Multivariate: 
NLR≥3: p = 0.15 
 
 
